Regulatory CD4⁺CD25⁺ cells reverse imbalances in the T cell pool of bone marrow transplanted Tgε26 mice leading to the prevention of colitis

C Veltkamp, R B Sartor, T Giese, F Autschbach, I Kaden, R Veltkamp, D Rost, B Kallinowski, W Stremmel

Background and aims: Erroneous thymic selection of developing T lymphocytes may be responsible for the expansion of self reactive T cells or may contribute to the absence of regulatory T cells important in controlling peripheral inflammatory processes. Colitis in bone marrow (BM) transplanted Tgε26 mice is induced by abnormally activated T cells developing in an aberrant thymic microenvironment. We investigated the protective role of regulatory CD4⁺CD25⁺ T cells in this model.

Methods: BM from (C57BL/6 x CBA/J) F1 mice was transplanted into specific pathogen free Tgε26 mice (BM→Tgε26). Transplanted mice received no cells (control), sorted CD4⁺CD25⁺, or CD4⁺CD25⁻ cells from mesenteric lymph nodes (MLN) of normal mice. MLN cell subsets were analysed using membrane markers. Cytokine secretion of MLN cells was measured using intracellular cytokine staining and cytokine secretion in anti-CD3 stimulated cell cultures. Colitis was measured by histological scores.

Results: CD4⁺CD25⁺ cells were reduced in the MLNs of BM→Tgε26 mice. Transfer of regulatory CD4⁺CD25⁺ but not of CD4⁺CD25⁻ cells reduced the number of MLN CD4⁺ T cells in BM→Tgε26 recipients and increased the number of MLN CD8⁺ cells, thereby normalising the CD4⁺/CD8⁺ ratio. CD4⁺CD25⁻ but not CD4⁺CD25⁺ cell transfer into BM→Tgε26 mice reduced the number of tumour necrosis factor α⁺ CD4⁺ cells and increased the secretion of transforming growth factor β by MLN cells. Transfer of 3×10⁷ CD4⁺CD25⁺ cells after BM transplantation into Tgε26 mice prevented colitis whereas CD4⁺CD25⁻ cells had no protective effect.

Conclusions: These results suggest that defective selection or induction of regulatory T cells in the abnormal thymus is responsible for the development of colitis in BM→Tgε26 mice. Transfer of CD4⁺CD25⁺ cells can control intestinal inflammation in BM→Tgε26 mice by normalising the number and function of the MLN T cell pool.

Regulatory CD4⁺CD25⁺ cells reverse imbalances in the T cell pool of bone marrow transplanted Tgε26 mice leading to the prevention of colitis

T he immune system of the distal intestine must discriminate between harmful foreign antigens and innumerable antigens from the complex resident bacterial flora. Under normal circumstances, immunological tolerance toward the commensal enteric bacterial flora prevents continuous intestinal inflammation. There is compelling evidence from both human and animal models that this controlled tolerance and immune system of the distal intestine must discriminate between harmful foreign antigens and innumerable antigens from the complex resident bacterial flora. Under normal circumstances, immunological tolerance toward the commensal enteric bacterial flora prevents continuous intestinal inflammation. There is compelling evidence from both human and animal models that this controlled tolerance and normalised flora.
and selection in the abnormally structured thymus are profoundly compromised. Consequently, aggressive CD4\(^+\) T cells develop while peripheral CD8\(^+\) cells are almost absent.\(^{23}\) CD4\(^+\) cells are characterised by low CD45RB\(^{high}\) expression and by secretion of a T helper 1 (Th1) cytokine profile consisting of interferon \(\gamma\) (IFN-\(\gamma\)) and tumour necrosis factor \(\alpha\) (TNF-\(\alpha\)).\(^{23}\) These cells cause severe colitis.\(^{23-26}\)

To date, the mechanisms underlying the development of aggressive T cells in the abnormal thymus in Tg2e26 mice have only been partially elucidated. Failure of the thymus to negatively select aggressive T cells is one possibility. Alternatively, a defect of positive selection of Treg cells in the thymus may cause loss of control. The latter hypothesis is more compatible with experiments in which transplantation of a normal thymus into BM\(\rightarrow\)Tg2e26 mice with a persistent abnormal thymus prevented the development of colitis.\(^{23}\) However, direct evidence for a key role of absent Treg cells in the pathogenesis of colitis in Tg2e26 mice is missing and such cells need to be further characterised.

The purpose of the present study was to investigate whether defective selection of CD4\(^+\)CD25\(^-\) Treg cells in the compromised thymic environment of Tg2e26 mice is responsible for the development of colitis after BM transplantation. Specifically, we sought to determine whether the aberrant activity of T cells derived from the thymus of BM\(\rightarrow\)Tg2e26 mice can be corrected by regulatory CD4\(^+\)CD25\(^+\) cells and to assess the mechanisms by which this correction is mediated.

### MATERIALS AND METHODS

#### Mice

Normal (C57BL/6 × CBA/J) F1 mice were purchased from Taconic M&B (Bomholtvej, Denmark), Tg2e26 mice, generated by overexpression (\(>30\) copies) of the full length human CD3e gene, were established by sibling breeding of animals on the C75BL/6 × CBA/J background under specific pathogen free (SPF) conditions at our local animal facility. All mice were 8–16 weeks old.

#### BM purification and transplantation

BM cells were harvested from tibias and fibulas of the C57BL/6 × CBA/J F1 mice. To avoid allorecognition of the Tg2e26 recipients, donor BM cells were depleted of mature T cells. This was achieved by two rounds of complement mediated lysis using anti-Thy1.2 monoclonal antibody (clone 30-H12; BD PharMingen, San Diego, California, USA) on ice for 30 minutes followed by rabbit complement (Cedarlane) at 37°C for 45 minutes. Thereafter, less than 0.1% CD4\(^+\) and 0.2% CD8\(^+\) T cells were present in the BM inoculum, as determined by flow cytometry. BM recipients were pretreated with 150 mg/kg 5-fluorouracil (Gry-Pharma, Germany) and antibiotics/antimycotics (penicillin G sodium/penicillin V potassium, St Louis, Missouri, USA), and resuspended in MACS buffer. Cells were depleted of CD8\(^+\) and B220\(^+\) cells by negative selection using antihuman coated Microbeads (Miltenyi Biotec). The resulting CD4\(^+\) enriched cells were stained with PE conjugated anti-CD4 and FITC conjugated anti-CD25 monoclonal antibodies. Subsets of CD4\(^+\) cells were generated by two colour sorting on a BD FACS Vantage SE/DiVa Option. All populations were >98% pure on reanalysis.

#### Flow cytometry

Isolated unseparated MLN cells were stained with FITC labelled antihuman CD4 and PE labelled antihuman CD8. Intracellular staining for TNF-\(\alpha\) and IL-10 was performed using MLN cells five hours after stimulation with immobilised anti-CD3 for TNF-\(\alpha\) and in addition anti-CD28 for IL-10. Brefeldin A (Sigma) was added two hours after culture initiation. Cells were first stained with antihuman CD4 PE. Before staining, cells were fixed with 3% paraformaldehyde (Riedel-de Haen, Seelze, Germany) and permeabilised using 0.5% saponin (Sigma). T cells were analysed on a FACScan flow cytometer (Becton Dickinson, Heidelberg, Germany) using CellQuest software. Isotype matched control antibody staining served as the zero value.

#### Antibodies

The following antibodies were used for cell purification: antihuman CD45R (B220) Microbeads (clone RA3-6B2) and antihuman CD8a (Ly-2) Microbeads (clone 53-6-7) (Miltenyi Biotec, Bergisch Gladbach, Germany); PE conjugated antihuman CD4 (clone GK1.5) and fluorescein isothiocyanate (FITC) conjugated antihuman CD25 (IL-2 receptor \(\alpha\) chain, p55) (clone 7D4) were used for FACS sorting. FITC conjugated antihuman CD4 (clone GK1.5) and PE conjugated antihuman CD8a (Ly-2) (clone 53-6-7) were used for FACS analysis after T cell depletion in BM and for T cell analysis in sacrificed mice. FITC conjugated antihuman IL-10 (clone JES5-16E3) and FITC conjugated antihuman TNF-\(\alpha\) (clone MP6-XT22) were used for intracellular cytokine staining. For cell stimulation, antihuman CD3 (CD3\(\epsilon\) chain, clone 145-2C11), and for IL-10 staining antihuman CD28 (clone 37.51), were used.

#### Cytokine assays

Transforming growth factor \(\beta\) (TGF-\(\beta\)), IL-10, IFN-\(\gamma\), and TNF-\(\alpha\) were measured in MLN culture supernatants prepared as previously described\(^{3}\) and analysed using standard ELISA techniques (R&D Systems, Germany).\(^{25}\) Concentrations of cytokines were established in duplicated culture supernatants by comparison with standard curves. Limits of detection are 7 pg/ml of TGF-\(\beta\), 4.0 pg/ml of IL-10, 2 pg/ml of IFN-\(\gamma\), and 5.1 pg/ml of TNF-\(\alpha\).

#### Statistical analysis

Parametric data were analysed by the Student \(t\) test and non-parametric data by the Mann-Whitney test. A \(p\) value of <0.05 was considered significant.
RESULTS

Regulatory CD4+CD25+ cells are reduced in BM transplanted Tg26 mice

We first investigated whether regulatory CD4+CD25+ cells were reduced in BM→Tg26 mice. Therefore, MLN cells of BM→Tg26 mice were analysed by flow cytometry in comparison with wild-type mice 4–6 weeks after BM transplantation. The percentage of MLN cells that expressed both CD4 and CD25 was lower in Tg26 mice with colitis than in healthy wild-type mice (colitic 1.5 (1.1%); wild-type 2.6 (1.0%); p<0.05) (fig 1).

CD4+CD25+ transfer partially normalises the proportion of MLN CD4+ and CD8+ cells

Analysis of the effect of Treg cells on the proportion of MLN cells revealed that the regulatory CD25+ cell fraction reduced the percentage of CD4+ cells in the MLN of reconstituted mice in comparison with transplanted mice, with no additional cell transfer (table 1). In contrast, CD4+CD25+ cell transfer slightly increased the fraction of CD4+ cells (table 1).

The result of 1.7 (0.8)% for CD8+ cells found in transplanted mice confirms previous results (table 1). Interestingly, the percentage of CD8+ cells in MLN increased significantly in response to CD4+CD25+ cell transfer (table 1). In contrast, CD4+CD25+ cells did not change the CD8+ population (table 1) which remained as low as in the BM→Tg26 mice. Thus CD4+CD25+ cell transfer normalised the ratio of CD4+ cells to CD8+ cells while transfer of CD4+CD25+ cells substantially increased the CD4/CD8 MLN cell ratio (table 1). Taken together, these data suggest that regulatory CD4+CD25+ cells reduce the pathogenic CD4+ T cells in BM→Tg26 mice and correct imbalances of peripheral T cell differentiation.

CD25+ regulatory cells reduce TNF-α producing cells dose dependently

In the BM→Tg26 mouse model, CD4+ cells operate via a Th1 cytokine profile with a predominance of TNF-α and IFN-γ production. Therefore, we studied the effect of CD4+CD25+ cells on MLN Th1 T cells in transplanted mice. Transfer of 3×10^5 MLN Treg cells significantly reduced TNF-α producing CD4+ MLN cells measured by FACS to as low as in wild-type mice (fig 2A). In contrast, transfer of lower numbers of CD4+CD25+ cells (1.5×10^5 cells) or CD4+CD25− cells (3.0×10^5 cells) was unable to reduce TNF-α producing CD4+ T cells (fig 2A). After stimulation of MLN cells with anti-CD3, MLN cells from CD4+CD25+ T cell reconstituted BM→Tg26 recipients tended to produce lower amounts of TNF-α and secreted significantly lower amounts of IFN-γ than MLN cells from BM transplanted CD4+CD25− cell reconstituted mice (fig 2B, C). These results indicate that Treg cells control intestinal inflammatory responses by reducing Th1CD4+ T cells. The regulatory effect of Treg cells was dose dependent.

Table 1

Analysis of mesenteric lymph node (MLN) cells derived from wild-type (WT) mice, from Tg26 mice after bone marrow (BM) transplant alone, or after bone marrow transplant plus CD4+CD25+ or CD4+CD25− cell transfer

<table>
<thead>
<tr>
<th>Mouse group</th>
<th>No of MLN cells ×10^6</th>
<th>No of CD4+ cells ×10^6 (% gated)</th>
<th>No of CD8+ cells ×10^6 (% gated)</th>
<th>Ratio CD4/CD8 cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>WT</td>
<td>16.4 (8.27)†</td>
<td>5.6 (1.9)†</td>
<td>2.7 (1.6)†</td>
<td>2.07 (2.28)</td>
</tr>
<tr>
<td>BM</td>
<td>34.0 (22.0)</td>
<td>4.1 (1.4)†</td>
<td>3.1 (0.9)†</td>
<td>1.30 (2.45)</td>
</tr>
<tr>
<td>BM+CD25+</td>
<td>29.0 (14.4)</td>
<td>7.2 (1.8)†</td>
<td>3.9 (0.9)†</td>
<td>1.86 (2.76)</td>
</tr>
<tr>
<td>BM+CD25−</td>
<td>23.0 (15.6)</td>
<td>6.4 (2.2)†</td>
<td>3.5 (1.4)†</td>
<td>1.82 (2.0)</td>
</tr>
</tbody>
</table>

*Mean (SEM) number of MLN cells, number (percentages) of MLN CD4+ and CD8+ T cells obtained from Tg26 mice transplanted with BM alone (n=12) or with CD4+CD25+ cells (n=8) or CD4+CD25− cells (n=12), from C57 Bl/6×CBA/JIF mice (n=20).
†p<0.01 versus BM→Tg26 mice, versus BM+CD4+CD25+ Tg26 mice, and versus BM+CD4+CD25− Tg26 mice.
‡p<0.05 versus BM+CD4+CD25+ Tg26 mice.
\*p<0.05 versus BM+CD4+CD25− Tg26 mice.

Figure 1 Flow cytometric analysis of expression of CD4+CD25+ in mesenteric lymph node (MLN) cells of Tg26 mice transplanted with wild-type bone marrow (BM→Tg26) (B) and of syngenic wild-type mice (A). Dot plots showing representative proportions of CD4+CD25+ MLN cells in Tg26 mice 4–6 weeks after bone marrow (BM) transplantation and in syngenic wild-type (WT) mice.
CD4+CD25+ cells prevent colitis in BM transplanted Tg26 mice

To investigate the regulatory activity of CD4+CD25+ cells in the prevention of colitis in Tg26 mice, we analysed the colon of BM transplanted mice (control) in comparison with three groups of mice which in addition to BM received 3×10^5 CD4+CD25+ cells, 1.5×10^5 CD4+CD25+ cells, or 3×10^5 CD4+CD25+ cells one week after transplantation. This time point was chosen to eliminate the chance that Treg cells given at the same time as BM transplant prevented engraftment of BM in the recipient. Transfer of 3×10^5 CD4+CD25+ cells inhibited weight loss (fig 3) and clinical signs of colitis in recipients while 1.5×10^5 CD4+CD25+ cells did not prevent weight loss (data not shown). Results were identical when CD4+CD25+ cells were transferred on the same day as BM (data not shown). In contrast, mice reconstituted with CD4+CD25− cells started to lose weight two weeks after BM transplantation (fig 3) and showed clinical signs of wasting and colitis (for example, piloerection, hunching, bloody diarrhoea). Within this group, two mice died two weeks after BM transplantation. The control group of only BM→Tg26 mice started to show clinical signs of inflammation, including weight loss four weeks after transplantation, confirming previous results (fig 3).23

![Intracytoplasmic staining of tumour necrosis factor α (TNF-α) production](image)

**Figure 2** Intracytoplasmic staining of tumour necrosis factor α (TNF-α) (A) and production of TNF-α (B) and interferon γ (IFN-γ) (C) measured by ELISA. (A) Summation of intracytoplasmic staining of TNF-α is shown on gated CD4+ mesenteric lymph node (MLN) cells from wild-type (WT) mice and from Tg26 mice transplanted with wild-type bone marrow (BM→Tg26) that received 3×10^5 CD4+CD25+ cells, 1.5×10^5 CD4+CD25+ cells, 3×10^5 CD4+CD25+ cells, or no T cells, as analysed by flow cytometry five hours after stimulation with immobilised anti-CD3 antibody. Mean (SEM) percentage of cytokine positive cells are shown. *p<0.05 versus BM→Tg26 mice that received 1.5×10^5 CD4+CD25+ cells, versus BM→Tg26 mice that received 3×10^5 CD4+CD25+ cells, and versus BM→Tg26 mice. (B) TNF-α and (C) IFN-γ in supernatants of MLN cultures three days after stimulation with anti-CD3 antibody. Values represent means (SEM) in supernatants of MLN cultures from BM→Tg26 mice that received 3×10^5 CD4+CD25+ cells or 3×10^5 CD4+CD25+ cells.
Histopathological analysis of the colon from untreated BM\(\rightarrow\)Tg\(\epsilon\)-26 mice showed inflammation in all parts, with the most severe inflammation in the distal colon and caecum. This was characterised by leucocyte infiltration in the mucosa and submucosa, prominent epithelial hyperplasia, loss of goblet cells, occasional crypt abscesses, and ulcerations (distal colon score 2.6 (0.5)) (fig 4, 5B). Transfer of \(3 \times 10^5\) CD4\(^+\)CD25\(^+\) cells led to an almost normal colon architecture with only a mild increase in leucocyte infiltration but no other signs of colitis (distal colon score 0.3 (0.3)) (fig 4, 5C). Lower transfer numbers of CD4\(^+\)CD25\(^+\) cells failed to prevent colitis (distal colon score 2.8 (0.4)) (fig 4, 5D). CD4\(^+\)CD25\(^-\) cell transfer did not prevent colitis (distal colon score 2.7 (0.3)) (fig 4, 5E). Thus CD4\(^+\)CD25\(^+\) cells prevented colitis in the BM\(\rightarrow\)Tg\(\epsilon\)-26 model while CD4\(^+\)CD25\(^-\) cells had no such regulatory function.

CD25\(^+\) Treg cells increase the secretion of TGF-\(\beta\) by MLN cells

Others have shown that Treg cell action depends at least in part on the secretion of anti-inflammatory cytokines.\(^{28-30}\) To gain further insight into the mechanism by which CD25\(^+\) cells exert their regulatory potential in the Tg\(\epsilon\)-26 intestine, we examined the production of TGF-\(\beta\) and IL-10 in MLN cells after stimulation with anti-CD3 and anti-CD28, respectively. Significantly higher levels of TGF-\(\beta\) were detected in supernatants of MLN cell cultures from CD4\(^+\)CD25\(^+\) cell reconstituted BM\(\rightarrow\)Tg\(\epsilon\)-26 mice in comparison with CD4\(^+\)CD25\(^-\) cell recipients (fig 6A). Intracytoplasmic staining showed that the frequency of IL-10 producing MLN CD4\(^+\) cells in Tg cell transferred Tg\(\epsilon\)-26 recipients was not increased (CD4\(^+\)CD25\(^+\) mice: 0.2 (0.29\%); CD4\(^+\)CD25\(^-\) mice: 0.19 (0.14\%); wild-type mice: 0.2 (0.56\%)). There was no

Figure 5 Photomicrographs of the colons of Tg\(\epsilon\)-26 mice five weeks after bone marrow (BM) transplant or after transplantation of BM plus transfer of different T cell subsets. Representative haematoxylin-eosin stained sections from the distal colon are shown (magnification 200\times\).

(A) Normal colon from a non-transplanted specific pathogen free (SPF) Tg\(\epsilon\)-26 mouse. (B) Severe colitis in a SPF BM transplanted Tg\(\epsilon\)-26 mouse demonstrating crypt hyperplasia, decreased goblet cells, pronounced lamina propria lymphocytic infiltration, and crypt abscesses. (C) No signs of inflammation in a Tg\(\epsilon\)-26 mouse that received BM plus \(3 \times 10^5\) CD4\(^+\)CD25\(^+\) cells. (D) Active colitis in a BM transplanted Tg\(\epsilon\)-26 mouse which was reconstituted with only \(1.5 \times 10^5\) CD4\(^+\)CD25\(^-\) cells. (E) Severe colitis in a SPF Tg\(\epsilon\)-26 mouse that was injected with BM plus \(3 \times 10^5\) CD4\(^+\)CD25\(^-\) cells. Extensive lamina propria cellular infiltration, crypt hyperplasia, and decreased goblet cells are evident.
convincing trend towards higher IL-10 secretion by MLN cells from CD4+CD25+ mice in comparison with CD4+CD25− mice (fig 6B). These results suggest that CD4+CD25+ cells down-regulate the immune response predominantly by production of TGF-β.

DISCUSSION

It is unclear whether the development of colitis in BM→Tg26 mice results from failure of negative selection of aggressive T cells in the abnormal thymus or from insufficient production of thymic dependent regulatory T cells. Our findings provide strong evidence for defective function of regulatory CD4+CD25+ T cells in the pathogenesis of bowel inflammation in this model. Firstly, CD25+ expression on CD4+ cells in the MLN was significantly lower in BM→Tg26 mice with colitis than in healthy wild-type animals. Interestingly, our findings correspond to recent results in IBD patients in whom intestinal CD4+CD25+ cells were decreased in active disease. Moreover, co-administration of CD4+CD25+ Treg cells from MLN of normal mice clearly protected against wasting and colitis in the BM→Tg26 model. In contrast, CD4+CD25− cells had no immunosuppressive effect, indicating that the regulatory function lies within the CD4+CD25+ T cell subset. Protection of colitis by CD4+CD25+ cells has been demonstrated in SCID and Rag mice. However, the immunological mechanisms of colitis in these models differ from the BM→Tg26 colitis model. Transfer of the naive CD4+CD45RB(high) T cell subset from wild-type mice into SCID/Rag mice induces colitis in the recipients. This can be prevented by co-injection of the antigen experienced subset of CD4+CD45RB(low) T cells. The CD25+ population comprises the inhibitory subset of CD4+CD45RB(low) T cells. In contrast, colitis in Tg26 mice is driven by CD4+CD45RB(low) cells, and CD45RB(low) cells from colitic Tg26 mice could transfer severe colitis to untransplanted Tg26 recipients. Prevention of colitis by CD4+CD25+ cells in BM→Tg26 mice demonstrates that pathogenic responses by not only naïve CD4+CD45RB(high) cells as in the SCID mouse model but also by activated colitis conferring CD4+CD45RB(low) cells are suppressed by CD4+CD25+ T cells. Adding to the complexity, Asseman et al reported that transfer of CD4+CD45RB(high) T cells into SCID mice can also induce colitis. However, colitis development was still different from the Tg26 model because it developed only when anti-IL-10R monoclonal antibody was co-administered. Furthermore, the ability of CD4+CD45RB(low) T cells to induce inflammation was significantly reduced when these cells were isolated from germ free mice. In contrast, in the Tg26 model, the colitis inducing CD4+CD45RB(low) cells are bacteria specific without further manipulation and have the functional capacity to induce colitis when transferred to specific pathogenic free recipients even when isolated from germ free BM→Tg26 mice. Based on our present study we speculate that the development of bacteria specific T cells may be due to the aberrant thymic selection of regulatory cells.

Differences in Treg cell mediated protection of colitis in the SCID mouse versus the Tg26 mouse is also visible in the number of Treg cells necessary to prevent inflammation. While Read and colleagues reported that 5x10^7 CD4+CD25+ cells were sufficient to prevent colitis in SCID mice, we had to transfer a minimum of 3x10^7 cells into BM→Tg26 mice for protection. In the Tg26 mouse a high number of very activated T cells develop after bone marrow transplantation. Thus differences in the number and also in the proinflammatory potential of colitic T cells in the two models might be responsible for the different Treg cell numbers necessary for the effects observed.

Our study examined the mechanisms by which CD4+CD25+ T cells prevented colitis. Protection in our experiments was seen as early as four weeks after cell transfer in contrast with the SCID mouse model in which complete protection became manifest 10 weeks after cell transfer. Delayed protection in SCID mice was interpreted as a sign that Treg cells suppress the inflammatory response via an indirect mechanism. Foussat et al proposed that Treg cells function indirectly by enhancing differentiation of IL-10 secreting T cells. Asseman et al suggested that IL-10 secretion by CD4+CD25+ T cells is not an absolute requirement for inhibition of colitis in the SCID model because CD4+CD25+ cells from IL-10−/− mice induced colitis. We detected only minimal and almost identical IL-10 on intracellular staining of MLN CD4+ cells from BM→Tg26 mice and BM→Tg26 reconstituted with either CD4+CD25+ or CD4+CD25− cells. There was no convincing trend towards higher IL-10 levels in the supernatants of MLN cell cultures from BM→Tg26 mice after reconstitution with CD4+CD25− T cells in comparison with mice that received CD4+CD25+ cells. A limitation of our study is that we did not transfer CD4+CD25+ cells from IL-10 deficient mice or neutralised IL-10 by a blocking antibody. Nevertheless, our data do not suggest a major role for IL-10 as the effector mechanism of protection conferred by CD4+CD25+ cells in this model.

TGF-β has been shown to be the key immunosuppressive cytokine in CD4+CD25+ regulatory cells in various disease models. Recently, it was demonstrated that TGF-β also converted CD4+CD25− naïve T cells to CD4+CD25+ Treg cells, These cells expressed the transcription factor Foxp3 which is associated with the development of Treg cells. In vivo data demonstrated that Foxp3 expressing Treg cells prevented colitis in SCID mice. In our experiments, TGF-β was
secreted in significantly higher amounts by MLN cells from BM=Tg26 mice that had received CD4+CD25+ cells compared with those receiving either BM or BM plus CD4+CD25+ cells. While this suggests that TGF-β is involved in the CD4+CD25+ cell mediated prevention of colitis in the Tg26 colitis model, we did not perform experiments with TGF-β blocking antibodies.

Protection against colitis by Treg cells was dose dependent in our model. Transfer of at least 3×10^5 Treg cells was necessary to prevent intestinal inflammation. Lower Treg cell transfer numbers led to a higher proportion of activated TNF-α producing T cells in recipients. Moreover, MLN T cells from Treg cell reconstituted mice secreted lower amounts of TNF-α and IFN-γ on stimulation than T cells from CD4+CD25+ reconstituted mice. Taken together, this suggests that down-regulation of activated T cells is one of the immunosuppressive mechanisms of Treg cells in the Tg26 colitis model.

In accordance with previous reports, analysis of MLN cells in BM=Tg26 mice demonstrated that most of the T cells were CD4+ while CD8+ T cells were very rare, thereby increasing the ratio of CD4+ to CD8+ T cells several fold in comparison with wild-type mice. Flow cytometry of MLN from BM=Tg26 mice reconstituted with CD4+CD25+ cells revealed a much lower number and percentage of CD4+ cells in comparison with mice reconstituted with CD4+CD25- cells and with BM=Tg26 mice without additional cell transfer. The number and percentage of CD8+ cells in MLN increased in response to transfer of CD4+CD25+ Treg cells while it remained low in CD4+CD25- treated mice. The effect on the peripheral T cell pool was also expressed in the ratio CD4+ to CD8+ cells, which was similar in Treg cell reconstituted and wild-type mice but remained largely increased in mice reconstituted with CD4+CD25- cells. Thus our results provide evidence that the aberrant proportion of peripheral T cells in BM=Tg26 mice is corrected by CD4+CD25+ cells.

Our observation that Treg cells regulate the development of CD8+ cells indicates an as yet undefined role for Treg cells in thymus dependent T cell development. Pettersson and colleagues showed that CD8+ T cells induced CD4+CD8-CD25+ thymocytes. These double positive thymocytes are absent in BM=Tg26 mice. We speculate that Treg cell induced CD8+ cells act in a positive loop inducing the development of double positive thymocytes, thereby promoting the normalisation of the Tg26 thymic architecture and T cell development.

In summary, our experiments show that CD4+CD25+ T cells play an important role in the prevention of intestinal inflammation in the Tg26 colitis model. CD4+CD25+ T cell transfer resulted in a substantial modification of the MLN T lymphocyte subsets. This may identify a possible new mechanism by which Treg cells induce immune suppression in experimental colitis.

**ACKNOWLEDGEMENTS**

We thank Dieter Stefan for excellent technical assistance with cell sorting. Jutta Scheurer for processing of histological samples, and Dr Juergen Weiss and staff for care of experimental animals. Supported by grants from the Forschungsforderungs-Programm of the University Hospital Heidelberg (154/2000) and the Dietmar-Hopp-Foundation.

**Authors’ affiliations**

C Veltkamp, I Kaden, D Rost, B Kallinowski, W Stremmel, Department of Gastroenterology, Ruprecht-Karls-University, Heidelberg, Germany

R B Sartor, Center for GI Biology and Disease, University of North Carolina, Chapel Hill, NC, USA

T Giese, Department of Immunology, Ruprecht-Karls-University, Heidelberg, Germany

F Autschbach, Department of Pathology, Ruprecht-Karls-University, Heidelberg, Germany

R Veltkamp, Department of Neurology, Ruprecht-Karls-University, Heidelberg, Germany

Conflict of interest: None declared.

**REFERENCES**


Regulatory CD4^+CD25^+ cells reverse imbalances in the T cell pool of bone marrow transplanted TG^ε^26 mice leading to the prevention of colitis

C Veltkamp, R B Sartor, T Giese, F Autschbach, I Kaden, R Veltkamp, D Rost, B Kallinowski and W Stremmel

Gut 2005 54: 207-214
doi: 10.1136/gut.2004.046953

Updated information and services can be found at:
http://gut.bmj.com/content/54/2/207

These include:

References
This article cites 41 articles, 24 of which you can access for free at:
http://gut.bmj.com/content/54/2/207#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/